News >

Coupling Novel Approaches With Chemo in Advanced Prostate Cancer

Caroline Seymour
Published: Tuesday, Oct 22, 2019

Daniel J. George, MD

Daniel J. George, MD
Data from the phase III CARD trial suggest that sequencing cytotoxic chemotherapy with novel androgen receptor (AR)-directed therapy has a role in the metastatic castration-resistant prostate cancer (mCRPC) setting, explained Daniel J. George, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication